Sanofi acquired Blueprint for $9.5 billion, adding rare disease portfolio to its business.
3 reports, 3 independent
Updated Jul 22
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi acquired Blueprint for $9.5 billion, adding rare disease portfolio to its business.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sanofi
company in Milan, Italy
Nothing else this week.
-
Blueprint
American longevity and health optimization company co-founded by Bryan Johnson and Kate Tolo.
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeySanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for
- Pharmaceutical TechnologySanofi concludes Blueprint Medicines acquisition Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the expertise of a company focu
- GlobeNewswirePress Release: Sanofi announces extension of Blueprint tender offer Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a w